Key points are not available for this paper at this time.
RIV4 provided better protection than standard-dose IIV4 against confirmed influenza-like illness among older adults. (Funded by Protein Sciences; ClinicalTrials.gov number, NCT02285998 .).
Dunkle et al. (Wed,) studied this question.